Bionano Genomics (BNGO)
NASDAQ:BNGO
Earnings Data
Report Date
May 13, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.87Last Year’s EPS
-1.15Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a mix of operational and commercial challenges alongside strong structural improvements. Management highlighted meaningful progress on profitability (1200 bps gross margin expansion), major operating expense reductions (~47% YoY), reimbursement wins (new CPT code and a 47% price increase), product and throughput upgrades, and scientific momentum with record publications. Offsetting these positives were modest revenue declines in 2025, Q4 supply constraints that limited consumable sales, a sizable Q4 software revenue timing hit (–22%), a concentrated customer base driving most consumable revenue, and relatively modest year-end liquidity. Management provided positive 2026 revenue guidance (5%–16% growth) and expects supply issues and debt retirement to help performance in 2026. Overall, the call leaned toward constructive execution progress and improving unit economics, while still requiring continued execution to translate margin and reimbursement gains into sustained top-line growth.Company Guidance
Full-Year Revenue and Guidance
Full-year 2025 revenue of $28.5M (down 7% YoY from $30.8M) with 2026 revenue guidance of $30M–$33M representing growth of ~5%–16% over 2025; Q1 2026 guidance of $6.5M–$6.7M (flat to +3%).
Non-GAAP Gross Margin Expansion
Non-GAAP gross margin improved to 47% for full-year 2025, up from 35% in 2024 — a 1,200 basis point improvement year over year; Q4 non-GAAP gross margin was 43% (vs. 42% a year ago).
Operating Expense and Cost Structure Transformation
Full-year 2025 non-GAAP operating expense was $36.6M, down 47% from $68.9M in 2024; Q4 non-GAAP operating expense was $9.7M, down 9% YoY. Since Q2 2023 the company removed approximately $100M of annualized non-GAAP operating expense and reduced headcount by over 300 people.
Consumables and Software Mix Shift Toward Higher-Quality Revenue
Consumables + software revenue grew to $20.4M for full-year 2025 (up 7% YoY from $19.0M) and increased as a share of total revenue from 62% to 71%, reflecting a strategic shift toward more predictable, higher-margin consumables and software revenue.
Installed Systems and Installations Outperformed Guidance
Installed 32 OGM systems in 2025, exceeding original guidance of 15–20 systems for the year; total installed base as of 12/31/2025 was 387 systems across 321 customers.
High-Value 'Routine-Use' Customer Base Driving Consumables
Approximately 130 routine-use customers (~40% of customers, ~45% of systems) drove ~83% of OGM consumables revenue. Average revenue per routine-use customer was ~$89K (about 2x the global average); 60 validated routine sites averaged ~$131K in consumables revenue.
Scientific Momentum and Publications Growth
Record year for OGM publications in 2025: 136 new peer-reviewed publications (up 25% YoY) and ~450 total publications (up from 359 in 2024). Clinical research genomes added ~1,190 in 2025, cumulative nearly 12,700 (CAGR ~30% since 2021).
Reimbursement Milestones Achieved
Established a second Category I CPT code for OGM (constitutional disorders) with a payment determination of $1,263.53; hematologic malignancy CPT payment increased 47% to $1,853.22 in 2026 CLFS — materially improving reimbursement infrastructure.
Product and Throughput Improvements
Commercial release of VIA 7.2 (extends automated workflows into constitutional disorders), Solve 3.8.3 (expanded control DB), and Stratus compute upgrade (advanced GPUs doubling weekly cancer sample throughput without hardware changes). IONIQ expansion supports high-purity DNA/RNA isolation at scale.
Operational Scale Evidence via Community and Partnerships
Bionano Symposium 2026 had >1,250 registrants from 73 countries; presentations highlighted scalable deployments (e.g., Radboud ramping to 3,000 samples/year, Labcorp showing Stratus can process up to 10,000 cancer samples/year) and cost/throughput advantages vs long-read sequencing.
Balance Sheet and Debt Milestone
Ended 2025 with $29.6M in cash, cash equivalents, and available-for-sale securities (including $10.3M restricted). Company expects cash runway into 2027 and senior secured convertible debt to be fully retired in May 2026, simplifying the balance sheet.
BNGO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BNGO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 23, 2026 | $1.46 | $1.18 | -19.18% |
Nov 13, 2025 | $1.47 | $1.52 | +3.40% |
Aug 14, 2025 | $3.21 | $3.04 | -5.30% |
May 14, 2025 | $3.74 | $3.93 | +5.08% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bionano Genomics (BNGO) report earnings?
Bionano Genomics (BNGO) is schdueled to report earning on May 13, 2026, After Close (Confirmed).
What is Bionano Genomics (BNGO) earnings time?
Bionano Genomics (BNGO) earnings time is at May 13, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BNGO EPS forecast?
BNGO EPS forecast for the fiscal quarter 2026 (Q1) is -0.87.